Age-related macular degeneration (AMD) is the most common cause of central vision loss and blindness in adults. Wet AMD comprises 25% of all cases of AMD and is characterized by new blood vessel ...

STOCKHOLM — A real-world analysis of retrospective data showed that administering more anti-VEGF injections over a 5-year time span to treat macular edema secondary to retinal vein occlusion (RVO) was ...

Please provide your email address to receive an email when new articles are posted on . Mynampati and colleagues measured VEGF levels in 59 eyes of patients with diabetic retinopathy (DR) who had ...

The use of anti-vascular endothelial growth factor injections has been linked to an increased risk of mortality in patients with diabetic retinopathy in a new study, sounding a note of caution ...

Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...

The FINANCIAL — A common treatment for wet age-related macular degeneration (AMD) may need a second thought by doctors of optometry. A new study suggests, in some cases, that patients’ vision worsens ...

Please provide your email address to receive an email when new articles are posted on . Staurenghi and colleagues conducted a 2-year, retrospective cohort study to assess the overall effectiveness of ...

4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of ...

Patients with type 2 diabetes who received intravitreal anti-vascular endothelial growth factor (VEGF) injections for diabetic retinopathy were more likely to develop systemic adverse events (AEs) ...

The FINANCIAL — Too much of a common age-related macular degeneration (AMD) treatment course in one year’s time could inadvertently tip the scales toward another sight-threatening disease, a new study ...